SLSSELLAS Life Sciences Group, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+34% of shares).
Choppy, but holding above its 200-day average. Price is +60% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SLS is trading
SELLAS Life Sciences Group, Inc. is +615% over the past year while the S&P 500 is +18%: 597 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +60%
vs 200-day average · a clear uptrend
- RSI (14)
- 53
RSI (14) · neutral
- Below its 52-week high
- 25%
Below its 52-week high
Details›
- Last close2026-10-09
- $11.66
- 1 monthS&P 500 +2.7%
- −14%
- 1 yearS&P 500 +18%
- +615%
- 5 yearsS&P 500 +88%
- +20%
- vs 50-day average$12.31
- −5.3%
- 52-week high
- $15.47
- 52-week low
- $1.39
- Annualised volatility
- 94%
| Year | Return |
|---|---|
| 2026 (year to date) | +209% |
| 2025 | +263% |
| 2024 | −1.9% |
| 2023 | −55% |
| 2022 | −57% |
| 2021 | −4.8% |
| 2020 | +35% |
| 2019 | −93% |
| 2018 | −84% |
| 2017 | −87% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +1.0% |
| Feb | 10 | 4 of 10 | −5.0% |
| Mar | 10 | 2 of 10 | −11% |
| Apr | 10 | 5 of 10 | +12% |
| May | 10 | 7 of 10 | +17% |
| Jun | 10 | 3 of 10 | −14% |
| Jul | 11 | 4 of 11 | −3.1% |
| Aug | 11 | 5 of 11 | −2.6% |
| Sep | 11 | 3 of 11 | −4.0% |
| Oct | 11 | 3 of 11 | +4.5% |
| Nov | 10 | 3 of 10 | −5.3% |
| Dec | 10 | 3 of 10 | +7.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.